揭示SGLT-2i的抗癌作用:机制和治疗潜力
Min Sun1, Jilei Sun2, Wei Sun3
1Department of Geriatrics, First Hospital, Jilin University, Changchun, China.
Frontiers in pharmacology
|April 10, 2024
概括
-葡萄糖共运输蛋白两抑制剂 (SGLT-2i),最初用于糖尿病,由于其抗癌性质,在癌症治疗中显示出希望. 需要进一步的研究来证实它们在瘤学中的有效性和安全性.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 癌症和糖尿病是复杂相互作用的主要健康问题.
- 同时存在的疾病往往需要多方面的治疗策略.
- -葡萄糖携带载体蛋白两抑制剂 (SGLT-2i) 是一种成熟的糖尿病治疗方法,具有新兴的非血糖益处.
研究的目的:
- 审查SGLT-2i在各种癌症类型中的潜在应用和机制.
- 探索SGLT-2i作为常规癌症治疗的潜在补充.
主要方法:
- 这项研究是对现有文献的叙述性审查.
- 它检查了SGLT-2i除了降低葡萄糖之外的特性.
- 该审查综合了关于SGLT-2i在非代谢性疾病,包括癌症中的作用的数据.
主要成果:
- 在心力衰竭和慢性病中,SGLT-2i具有额外的血糖指标特性.
- 它们在糖尿病中的耐受性表明,它们有可能用于癌症治疗.
- 在癌症治疗中,SGLT-2i可能提供了一个有前途的补充作用.
结论:
- SGLT-2i代表了癌症管理的潜在治疗候选者.
- 需要进一步的研究来阐明特定的抗瘤作用和机制.
- 临床试验对于评估安全性,可行性和最佳结合策略与现有癌症治疗方法至关重要.
相关概念视频
Glucose Transporters
22.7K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.7K
Secondary Active Transport
7.0K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.0K
Glucagon-like Receptor Agonists
319
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Dipeptidyl Peptidase 4 Inhibitors
182
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
182
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174


